{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T10:15:19Z","timestamp":1780654519941,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Czech Ministry of Health","award":["17-29520A"],"award-info":[{"award-number":["17-29520A"]}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["SVV 260 393"],"award-info":[{"award-number":["SVV 260 393"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["Q39"],"award-info":[{"award-number":["Q39"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ejinme.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ejim.2017.07.018","type":"journal-article","created":{"date-parts":[[2017,7,26]],"date-time":"2017-07-26T11:45:36Z","timestamp":1501069536000},"page":"55-61","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8023-3749","authenticated-orcid":false,"suffix":"Jr","given":"Otto","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Bruthans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitka","family":"Seidlerov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Karnosov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Van\u011bk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark\u00e9ta","family":"Hronov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Gel\u017einsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cv\u00ed\u010dela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Wohlfahrt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"C\u00edfkov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Filipovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2017.07.018_bb0005","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2337\/diacare.28.7.1769","article-title":"Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence","volume":"28","author":"Ford","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2017.07.018_bb0010","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1001\/jama.287.3.356","article-title":"Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey","volume":"287","author":"Ford","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2017.07.018_bb0015","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"Alberti","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.07.018_bb0020","doi-asserted-by":"crossref","DOI":"10.1093\/med\/9780199656653.003.0026","article-title":"EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries","author":"Kotseva","year":"2015","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ejim.2017.07.018_bb0025","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/ajcn\/85.5.1197","volume":"85","author":"Klein","year":"2007","journal-title":"Am. J. Clin. Nutr."},{"key":"10.1016\/j.ejim.2017.07.018_bb0030","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1093\/eurheartj\/ehr112","article-title":"Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management","volume":"32","author":"Chapman","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejim.2017.07.018_bb0035","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1194\/jlr.P002816","article-title":"Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database","volume":"51","author":"Barter","year":"2010","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejim.2017.07.018_bb0040","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/oxfordjournals.eurheartj.a015136","article-title":"A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events","volume":"18","author":"EUROASPIRE","year":"1997","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejim.2017.07.018_bb0045","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1053\/euhj.2001.2610","article-title":"Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme","volume":"22","author":"Anon","year":"2001","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejim.2017.07.018_bb0050","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/HJR.0b013e3283294b1d","article-title":"EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries","volume":"16","author":"Kotseva","year":"2009","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"10.1016\/j.ejim.2017.07.018_bb0055","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","volume":"33","author":"Perk","year":"2012","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejim.2017.07.018_bb0060","doi-asserted-by":"crossref","first-page":"515","DOI":"10.2217\/clp.14.49","article-title":"The hypertriglyceridemic waist is associated with an increased risk of inappropriate long-term glucose control in stable patients with chronic coronary heart disease","volume":"9","author":"Mayer","year":"2014","journal-title":"J. Clin. Lipidol."},{"key":"10.1016\/j.ejim.2017.07.018_bb0065","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.metabol.2015.06.019","article-title":"Risk of major adverse cardiovascular events in patients with metabolic syndrome after revascularization: A meta-analysis of eighteen cohorts with 18,457 patients","volume":"64","author":"Tie","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.ejim.2017.07.018_bb0070","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.athoracsur.2011.10.066","article-title":"Metabolic syndrome affects midterm outcome after coronary artery bypass grafting","volume":"93","author":"Angeloni","year":"2012","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.ejim.2017.07.018_bb0075","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000076695","article-title":"Which features of the metabolic syndrome predict the prevalence and clinical outcomes of angiographic coronary artery disease?","volume":"101","author":"Anderson","year":"2004","journal-title":"Cardiology"},{"key":"10.1016\/j.ejim.2017.07.018_bb0080","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.numecd.2011.05.002","article-title":"Impact of metabolic syndrome on clinical outcomes after new generation drug-eluting stent implantation: the 'obesity paradox' phenomenon is still apparent","volume":"23","author":"Patsa","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"10.1016\/j.ejim.2017.07.018_bb0085","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2017.07.018_bb0090","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.ejim.2017.07.018_bb0095","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects","volume":"363","author":"James","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2017.07.018_bb0100","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2337\/dc10-1318","article-title":"A1C and cardiovascular outcomes in type 2 diabetes: a nested case-control study","volume":"34","author":"Colayco","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2017.07.018_bb0105","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/S0140-6736(09)61969-3","article-title":"Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study","volume":"375","author":"Currie","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.07.018_bb0110","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1210\/jc.2012-3042","article-title":"Mortality and other important diabetes-related outcomes with insulin vs other antihyperglycemic therapies in type 2 diabetes","volume":"98","author":"Currie","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejim.2017.07.018_bb0115","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1463-1326.2010.01349.x","article-title":"Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials","volume":"13","author":"Lamanna","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.ejim.2017.07.018_bb0120","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2017.07.018_bb0125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2337\/dc10-1393","article-title":"Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database","volume":"34","author":"Best","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejim.2017.07.018_bb0130","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.amjcard.2012.04.061","article-title":"Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus","volume":"110","author":"Patil","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejim.2017.07.018_bb0135","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2017.07.018_bb0140","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejim.2017.07.018_bb0145","article-title":"The changes in cardiovascular prevention practice between 1995 and 2012 in the Czech Republic. A comparison of EUROASPIRE I, II, III and IV study","author":"Mayer","year":"2013","journal-title":"Cor Vasa"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620517302868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,29]],"date-time":"2018-08-29T19:55:22Z","timestamp":1535572522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620517302868"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":29,"alternative-id":["S0953620517302868"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2017.07.018","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective study of metabolic syndrome as a mortality marker in chronic coronary heart disease patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2017.07.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}